header
Image from OpenLibrary

Evaluation of response to different treatment regimens in patients with burkitt's lymphoma and mature B - ALL : A retrospective study / Asmaa Ahmed Mahmoud Ahmed ; Supervised Thoraya M. Abdelhamid , Fouad M. AboTaleb , Asmaa Ibrahim Salama

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Asmaa Ahmed Mahmoud Ahmed , 2014Description: 153 P. ; 25cmOther title:
  • {uFE97}{uFED8}{uFBFF}{uFBFF}{uFEE2} {uFEE3}{uFEAA}ى ا{uئإآ٣}{uئإ٩٨}{uئإء٠}{uئإ٨إ}{uئإ٩١}{uئإ٩٤} {uئإإ٣}{uئإءإ}{uئإآئ}{uئإئ٠} {uئإآ٣}{uئإءإ}{uئإأ٣}{uئإ٨إ}ن ا{uئإؤئ}{uئإؤ٠}{uئإءء}د ا{uئإؤئ}{uئإإ٠}{uئآئئ}{uئإإ٤}{uئإؤ٤}{uئإ٨إ}و{uئآئإ}{uئإ٩٤} {uئإإ٣}{uئإإ٦} {uئإإ٧}{uئإإإ}ع {uئإ٩١}{uئإءإ}{uئإؤآ}{uئإ٩٦} و {uئإآ٣}{uئإءإ}{uئإأ٣}{uئإ٨إ}ن ا{uئإؤئ}{uئإءء}م ا{uئإؤئ}{uئإإ٠}{uئآئئ}{uئإإ٤}{uئإؤ٤}{uئإ٨إ}وى ا{uئإؤئ}{uئإء٤}{uئإ٨إ}د {uئإإ٣}{uئإإ٦} {uئإإ٧}{uئإإإ}ع ا{uئإؤئ}{uئإء٨}{uئإئأ}{uئآئإ}{uئإ٨إ} {uئإ٩١}{uئإئ٠} ا{uئإؤئ}{uئإإ٨}{uئإ٨إ}{uئإآئ}{uئإء٠}{uئإ٩٤} لبرو{uئإ٩٧}{uئإإإ}{uئإؤآ}{uئإإإ}{uئإئآ}ت ا{uئإؤئ}{uئإأأ}{uئإئأ}ج ا{uئإؤئ}{uئإؤأ}{uئآئئ}{uئإإ٤}{uئإ٨إ}وى ا{uئإؤئ}{uئإإ٤}{uئإء٨}{uئإ٩٨}{uئإإ٠}{uئإؤ٤}{uئإ٩٤} : درا{uئإآ٣}{uئإ٩٤} {uئإإ٣}{uئإءإ}{uئإ٩ئ}{uئإأأ}{uئآئئ}{uئإ٩٤} [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Medical Oncology Summary: This is a retrospective study, based on assessment of patients with burkitt's lymphoma/ leukemia from 2006 to 2012. This study reports two centers experience of adult burkitt's lymphoma/ leukemia therapy with two different induction regimens. 47 adult patients with newly diagnosed burkitt's lymphoma/ leukemia were treated at the Medical oncology departments of NCI, Cairo University and of Zagazig university hospitals. These patients received induction chemotherapy with either modified CALGB 9251 or modified Hyper-CVAD. The complete remission (CR) rate was 76.9% in the modified CALGB 9251 group and 70.6% in the modified Hyper-CVAD group in burkitt's lymphoma patients. The main cause of death was induction related death due to chemotherapy toxicity in the group of patients who received modified CALGB 9251, but within the group who received modified hyperCVAD the main cause of death was disease progression
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.19.04.M.Sc.2014.As.E (Browse shelf(Opens below)) Not for loan 01010110065461000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.19.04.M.Sc.2014.As.E (Browse shelf(Opens below)) 65461.CD Not for loan 01020110065461000

Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Medical Oncology

This is a retrospective study, based on assessment of patients with burkitt's lymphoma/ leukemia from 2006 to 2012. This study reports two centers experience of adult burkitt's lymphoma/ leukemia therapy with two different induction regimens. 47 adult patients with newly diagnosed burkitt's lymphoma/ leukemia were treated at the Medical oncology departments of NCI, Cairo University and of Zagazig university hospitals. These patients received induction chemotherapy with either modified CALGB 9251 or modified Hyper-CVAD. The complete remission (CR) rate was 76.9% in the modified CALGB 9251 group and 70.6% in the modified Hyper-CVAD group in burkitt's lymphoma patients. The main cause of death was induction related death due to chemotherapy toxicity in the group of patients who received modified CALGB 9251, but within the group who received modified hyperCVAD the main cause of death was disease progression

Issued also as CD

There are no comments on this title.

to post a comment.